Showing results (221-230 of 6,499) with videos related to
Sort By:
Pageof 650
Cancer Immunology, Immunotherapy : CII|February 18, 2006
Antitumor action and immune activation through cooperation of bee venom secretory phospholipase A2 and phosphatidylinositol-(3,4)-bisphosphateThomas Putz, Reinhold Ramoner, Hubert Gander, et al.Cancer Immunology, Immunotherapy : CII|February 18, 2006
Immunomodulatory impact of interferon-alpha in combination with chemoradiation of pancreatic adenocarcinoma (CapRI)Jan Schmidt, Emilia M Patrut, Jianhua Ma, et al.Cancer Immunology, Immunotherapy : CII|February 18, 2006
PankoMab: a potent new generation anti-tumour MUC1 antibodyAntje Danielczyk, Renate Stahn, Dorian Faulstich, et al.Cancer Immunology, Immunotherapy : CII|January 6, 1999
Spontaneous T cell responses to melanoma differentiation antigens from melanoma patients and healthy subjectsQ Chen, H Jackson, P Gibbs, et al.Cancer Immunology, Immunotherapy : CII|January 6, 1999
Milky spots in the greater omentum are predominant sites of local tumour cell proliferation and accumulation in the peritoneal cavityL F Krist, M Kerremans, D M Broekhuis-Fluitsma, et al.Cancer Immunology, Immunotherapy : CII|February 28, 2002
Induction of intratumoral tumor necrosis factor by a synthetic lipid A analog, ONO-4007, with less tolerance in repeated administration and its implication in potent antitumor effects with low toxicityMotonobu Satoh, Kazusa Tsurumaki, Hideaki Kagehara, et al.Cancer Immunology, Immunotherapy : CII|February 28, 2002
SV40 Tag-specific cytotoxic T lymphocytes generated from the peripheral blood of malignant pleural mesothelioma patientsRobert K Bright, Eric T Kimchi, Michael H Shearer, et al.Cancer Immunology, Immunotherapy : CII|January 13, 2006
The identification of human tumour antigens: Current status and future developmentsAmanda K Miles, Balwir Matharoo-Ball, Geng Li, et al.Cancer Immunology, Immunotherapy : CII|February 15, 2002
Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell linesPina M Cardarelli, Maire Quinn, Dana Buckman, et al.Cancer Immunology, Immunotherapy : CII|November 26, 1998
Antitumor activity exhibited by Fas ligand (CD95L) overexpressed on lymphoid cells against Fas+ tumor cellsM Shimizu, Y Takeda, H Yagita, et al.Pageof 650